Showing results (541-550 of 3,096) with videos related to
Sort By:
Pageof 310
Expert Review of Anticancer Therapy|July 24, 2013
The role of necroptosis, an alternative form of cell death, in cancer therapyXinfang Yu, Qipan Deng, Ann M Bode, et al.Expert Review of Anticancer Therapy|March 20, 2013
Dermatologic adverse events associated with afatinib: an oral ErbB family blockerMario E Lacouture, Dirk Schadendorf, Chia-Yu Chu, et al.Expert Review of Anticancer Therapy|April 17, 2012
ROS1 as a 'druggable' receptor tyrosine kinase: lessons learned from inhibiting the ALK pathwaySai-Hong Ignatius Ou, Jackie Tan, Yun Yen, et al.Expert Review of Anticancer Therapy|April 17, 2012
Multimodal treatment strategies for locally advanced rectal cancerGeorg F Weber, Robert Rosenberg, Janet E Murphy, et al.Expert Review of Anticancer Therapy|April 17, 2012
Maintenance therapy for advanced non-small-cell lung cancer: ready for clinical practice?Anne Sibille, Isabelle Wauters, Johan VansteenkisteExpert Review of Anticancer Therapy|September 10, 2014
Exploring the potential of immuno-oncology-based treatment for patients with non-small cell lung cancerDavid Heigener, Martin ReckExpert Review of Anticancer Therapy|September 11, 2014
FOLFIRINOX - a new paradigm in the treatment of pancreatic cancerDionysios Papadatos-Pastos, Kiruthikah Thillai, Roy Rabbie, et al.Expert Review of Anticancer Therapy|November 27, 2012
Potential of whole-genome sequencing for determining risk and personalizing therapy: focus on AMLUma Borate, Devin Absher, Harry P Erba, et al.Expert Review of Anticancer Therapy|November 27, 2012
Follow-up recommendations and risk-reduction initiatives for Lynch syndromeCarmen Guillén-Ponce, Maria-José Molina-Garrido, Alfredo CarratoExpert Review of Anticancer Therapy|November 28, 2012
Primary resistance to tyrosine kinase inhibitors in patients with advanced renal cell carcinoma: state-of-the-scienceCamillo Porta, Roberto Sabbatini, Giuseppe Procopio, et al.Pageof 310